Faculty Publications

Hasmik Agadjanian, PhD


Sims, J. D., Taguiam, J. M., Alonso-Valenteen, F., Markman, J., Agadjanian, H., Chu, D., Lubow, J., Abrol, R., Srinivas, D., Jain, A., Han, B., Qu, Y., Mirzadehgan, P., Hwang, J-Y., Rentsendorj, A., Chung, A., Lester, J., Karlan, B. Y., Gray, H. B., Gross, Z., Giuliano, A., Cui, X., Medina-Kauwe L. K. (2018). Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics. Journal of Controlled Release, 271,127-138. https://doi.org/10.1016/j.jconrel.2017.12.024

Beach, J.A., Aspuria, P-J. P., Cheon, D-J., Lawrenson, Agadjanian, H., Walsh, C., Karlan, B.Y., & Orsulic, S. (2015). Sphingosine kinase 1 is required for TGF-? mediated fibroblastto-myofibroblast differentiation in ovarian cancer. Oncotarget, 7 (4), 4167-4182.

Cohen, J. G., Prendergast, E., Geddings, J. E., Walts, A. E., Agadjanian, H., Hisada, Y., Karlan B.Y., Mackman N., & Walsh, C. S. (2017). Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer. Gynecologic Oncology, 146(1), 146-152. doi:10.1016/j.ygyno.2017.04.021

Liu, Z., Beach, J.A., Agadjanian, H., Jia, D., Aspuria, P-J., Karlan, B.Y., & Orsulic, S. (2015). Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Gynecologic Oncology, 139, 394-400. DOI:10.1016/j.ygyno.2015.08.026 · 3.77

Taylor-Harding, B., Aspuria, P-J, Agadjanian, H., Cheon, D-J, & Wiedemeyer, W.R. (2014). CyclinE and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. Oncotarget, 6 (2), 696-714.

Diaz, E., Agadjanian, H., Nassanian, H., Walts, A., Miller, C., Karlan, B., Osulic, S., & Walsh C. (2013). PI3K pathway activation, thromboembolism and survival in ovarian cancer cell carcinoma. Gynecologic Oncology, 130(1) e.128. DOI:10.1016/j.ygyno.2013.04.367

Agadjanian, H., Chu, D., Hwang, J.Y., Wachsmann-Hogiu, S., Rentsendorj, A., Song, L., Valluripalli, V., Lubow, J., Ma, J., Sharifi, B., Farkas, D.L.,& Medina-Kauwe, L.K. (2012). Chemotherapy targeting by DNA capture in viral protein particles. Nanomedicine, 7(3), 335-352. DOI: 10.2217/nnm.11.104

Taylor-Harding, B., Agadjanian, H., Nassanian, H., Kwon, S., Guo, X., Miller, C., & Karlan, B.Y. Orsulic, S., and Walsh, C.S. (2012). Indole-3-carbinol synergistically sensitizes ovarian cancer cells to bortezomib treatment. British Journal of Cancer, 106, 333 – 343.

Fleming, N. D., Agadjanian, H., Nassanian, H., Miller, C. W., Orsulic, S., Karlan B. Y., & Walsh C. S. (2012). Xeroderma Pigmentosum Complementation Group C Single-Nucleotide Polymorphisms in the Nucleotide Excision Repair Pathway Correlate With Prolonged Progression-Free Survival in Advanced Ovarian Cancer. Cancer, 118, 689-697.

Liu Z, Beach JA, Agadjanian H, Jia D., Aspuria P, Karlan BY, Orsulic S. (2016). Abstract B64: Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B64

Taylor-Harding B, Agadjanian H, Aspuria P, Cheon, D., Mizuno T, Greenberg D, Allen JR, Orsulic S, Walsh C, Karlan BY, Wiedemeyer WR. (2014). Abstract 678: The Ets factor ETV5 regulates E2F target genes and mediates drug resistance Cancer Research. 74: 678-678. DOI: 10.1158/1538-7445.Am2014-678

Agadjanian H, Cheon D., Diaz E, Laury A, Miller C, Karlan B, Orsulic S, Walsh C. (2013). Abstract 329: A mouse model of epithelial ovarian cancer with defined oncogenic drivers. Cancer Research. 73: 329-329. DOI: 10.1158/1538-7445.Am2013-329

Taylor-Harding B, Agadjanian H, Orsulic S, Walsh C, Karlan BY, Wiedemeyer W. (2013). Abstract 1749: Cell cycle requirements shape ovarian cancer progression. Cancer Research. 73: 1749-1749. DOI: 10.1158/1538-7445.Am2013-1749

Taylor-Harding B, Agadjanian H, Aspuria PJ, Mizuno T, Cheon D., Orsulic S, Karlan B, Walsh C, Wiedemeyer WR. (2013). Abstract B48: Targeting chemo-resistance in CCNE1-amplified ovarian cancer Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B48


Walsh, C., Nassanian, H., Agadjanian, H., Miller, C., Orsulic, S., & Karlan, B. (2015).
Abstract BIOL-1348. No association between PARK2 and BRCA1-associated gynecologic cancers. Cancer Research, 21(16 Supplement): POSTER-BIOL-1348. DOI:10.1158/1557-3265.OVCASYMP14

Taylor-Harding, B., Agadjanian, H., Aspuria, P-J., Mizuno, T., Cheon, D-J., Orsulic, S., Karlan, B., Walsh, C., & Wiedemeyer, W.R. (2014). Abstract B48. Targeting chemo-resistance in CCNE1-amplified ovarian cancer. Clinical Cancer Research, 19, B48.

Agadjanian, H., Cheon, D-J, Diaz, E., Laury, A., Miller, C., Orsulic, S., & Walsh C. (2013). Abstract 329. A mouse model of epithelial ovarian cancer with defined oncogenic drivers. Cancer Research, 73(8 supplement) p.329.

Taylor-Harding, B., Agadjanian, H., Orsulic, S., Walsh, C., Karlan, B., & Wiedemeyer, W.R. (2013). Abstract 1749. Cell Cycle requirements shape ovarian cancer progression. Cancer Research, 73, p.1749.

Request Info

By clicking below, I consent to receive calls, emails and/or text messages* by a university representative with information for educational opportunities at the number(s) provided above. I understand calls may be initiated by an automated telephone dialing system. I need not grant this consent to receive information or to be eligible to enroll with WCU. I also understand that if I no longer wish to receive text messages from WCU, I can text back “Stop” at any time to unsubscribe from the service. *Standard rates may apply.

Personal Information you submit through our Sites, such as your name, address and other contact information, may be collected by West Coast University for internal marketing and development purposes as well as to respond to your inquiry, complete a transaction for you, or fulfill other forms of customer service. You can choose not to receive marketing from us by “unsubscribing” using the instructions in any marketing email you receive from us.

Click here to learn more.